2025
LUMATEPERONE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER WITH ANXIOUS DISTRESS AND MIXED FEATURES
Bhagwagar *, Kozauer S, Earley W, Huo J, Sachs G, Durgam S. LUMATEPERONE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER WITH ANXIOUS DISTRESS AND MIXED FEATURES. The International Journal Of Neuropsychopharmacology 2025, 28: i316-i316. PMCID: PMC11814723, DOI: 10.1093/ijnp/pyae059.563.Peer-Reviewed Original ResearchClinical Global Impression Scale-SeverityMajor depressive disorderMADRS total scoreClinical Global Impression Scale-Severity scoresAnxious distressBipolar depressionBipolar II disorderDSM-5Bipolar disorderTotal scoreII disorderBipolar IDepressive disorderDepressive episodeAssociated with major depressive disorderDepression Rating ScaleDSM-5 criteriaBipolar disorder diagnosisPost-hoc analysis of studyIncreased suicide riskPoor treatment responseSingle-item scoresEpisode specifierTreat schizophreniaDisorder diagnosis
1986
The functional status questionnaire
Jette A, Davies A, Cleary P, Calkins D, Rubenstein L, Fink A, Kosecoff J, Young R, Brook R, Delbanco T. The functional status questionnaire. Journal Of General Internal Medicine 1986, 1: 143-149. PMID: 3772582, DOI: 10.1007/bf02602324.Peer-Reviewed Original ResearchConceptsFunctional Status QuestionnaireBeth Israel HospitalFunctional statusStatus QuestionnaireFunctional assessmentBoston's Beth Israel HospitalPatients' functional statusInternal medicine practiceComprehensive functional assessmentSystematic functional assessmentBusy clinical practiceSelf-administered questionnaireSingle-item scoresAmbulatory patientsPrimary careOne-page reportClinical practiceRegular usersScale scoreMedicine practiceRole functionIsrael HospitalHealthcare associatesConstruct validityFeasible assessment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply